Clinical trials: Dapagliflozin (Forxiga)
Dapagliflozin (Forxiga), Atrial Fibrillation (AF)
Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
Investigator study the efficacy and safety outcomes of Dapagliflozin use among newly diagnosed Atrial fibrillation patients when underwent rhythm control strategy regardless their diabetic status.
- Trial name
- NCT06759909
- Testing
- Dapagliflozin (DAPA)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Type 2 Diabetes Mellitus
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
This surveillance is a postmarketing commitment following the marketing authorization for Forxiga(dapagliflozin) in accordance with Standards on Re-examination of New Drugs, notified by the MFDS under Article 32, Paragraph 1 and…
- Trial name
- NCT02252224
- Where
- 6 sites in South Korea
- Volunteers
- 3,123 people
- Sponsor
- AstraZeneca
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University